flexible and safe - algol diagnostics · intuitive and safe oncology infusion safe administration...

2
MEDICAL DEVICES Oncology Volumat Lines for Volumat Agilia Infusion Pumps Safe Oncology Administration of IV Cytostatics Efficiency with intuitive technology The special “Primary Secondary mode” in the Volumat MC Agila pump enables the administration of a multi-drug therapy with secondary infusions using the same pump. This increases the compliance with the prescribed cytostatic regime and saves nursing time. The complex regimes in oncology require flexibility and safe product solutions for the administration of IV cytostatics. The new Oncology Volumat and Secondary Lines offer a perfect solution and fulfill these requirements. The Secondary Lines prepared in the pharmacy can easily be connected to the needle-free access ports on the multi- access primary infusion set. This allows easily manageable multi-drug therapies in addition to the standard single drug therapy. Flexible and Safe A broad range of Oncology Volumat Lines for single drug therapy is available. The various features allow an easy and safe administration of all types of cytostatic regimes such as special infusion filters, PVC-free lines or light protection. The Primary Infusion Sets for the multi-drug therapy are designed to connect up to 4 secondary infusions. This allows a complete drug delivery without the need for disconnection of the system after the regime, thus avoiding the risk of contamination and reducing the loss of drugs in the line. Single drug therapy Multi-drug therapy NaCl Drug 1 Patient Patient NaCl Drug 1 Drug 2 single or multi Order information Oncology Volumat Lines for Volumat Agilia and Volumat MC Agilia Name DEHP-free PVC-free FX-spike K-Nect* 0,2μ Filter amber Ref. No. VL ON10 M46445500 VL ON20 M46445700 VL ON30 M46445900 VL ON40 M46445100 VL ON11 1 M46443900 VL ON12 1 M46444800 VL ON12 FX 2 M46444850 VL ON21 2 M46444700 VL ON22 2 M46444200 VL ON22 OP 2 M46446000 VL ON22 FX 3 M46444250 VL ON 42 4 M46444000 VL ON42 OP 4 M46445800 VL ON42 FX 5 M46444050 VL ON 70 M46444600 VL ON72 1 M46444100 VL ON 90 M46444900 VL ON90 FX 2 M46444960 Secondary line M77460020 Secondary line with Filter M77460025 Secondary line FX M77460021 Secondary line FX with Filter M77460026 * K-Nect needle free access with Tru-Swab TM Technology, provides a flat and smooth surface for optimal swabability, easy to clean to meet highest hygiene standards. It allows an easy and safe Luer-Lock connection of the secondary infusion to the primary infusion line. Fresenius Kabi AG D-61346 Bad Homburg v.d.H Germany Phone: +49 (0) 6172 686-0 www.fresenius-kabi.com 5762-0_bro_oncology_volumat_lines_eng

Upload: leanh

Post on 06-Mar-2019

219 views

Category:

Documents


0 download

TRANSCRIPT

M E D I C A L D E V I C E S

Oncology Volumat Linesfor Volumat Agilia Infusion PumpsSafe Oncology Administration of IV Cytostatics

Effi ciency with intuitive technologyThe special “Primary Secondary mode” in the Volumat MC Agila pump enables the administration of a multi-drug therapy with secondary infusions using the same pump. This increases the compliance with the prescribed cytostatic regime and saves nursing time.

The complex regimes in oncology require fl exibility and safe product solutions for the administration of IV cytostatics. The new Oncology Volumat and Secondary Lines offer a perfect solution and fulfi ll these requirements. The Secondary Lines prepared in the pharmacy can easily be connected to the needle-free access ports on the multi-access primary infusion set. This allows easily manageable multi-drug therapies in addition to the standard single drug therapy.

Flexible and Safe

A broad range of Oncology Volumat Lines for single drug therapy is available. The various features allow an easy and safe administration of all types of cytostatic regimes such as special infusion fi lters, PVC-free lines or light protection.

The Primary Infusion Sets for the multi-drug therapy are designed to connect up to 4 secondary infusions. This allows a complete drug delivery without the need for disconnection of the system after the regime, thus avoiding the risk of contamination and reducing the loss of drugs in the line.

Single drug therapy Multi-drug therapy

NaCl

Drug 1

Patient Patient

NaCl Drug 1 Drug 2singleor multi

Order information Oncology Volumat Lines for Volumat Agilia and Volumat MC Agilia

Name DE

HP

-fre

e

PV

C-f

ree

FX

-spi

ke

K-N

ect*

0,2

µ F

ilter

ambe

r

Ref. No.

VL ON10 M46445500

VL ON20 M46445700

VL ON30 M46445900

VL ON40 M46445100

VL ON11 1 M46443900

VL ON12 1 M46444800

VL ON12 FX 2 M46444850

VL ON21 2 M46444700

VL ON22 2 M46444200

VL ON22 OP 2 M46446000

VL ON22 FX 3 M46444250

VL ON 42 4 M46444000

VL ON42 OP 4 M46445800

VL ON42 FX 5 M46444050

VL ON 70 M46444600

VL ON72 1 M46444100

VL ON 90 M46444900

VL ON90 FX 2 M46444960

Secondary line M77460020

Secondary line with Filter

M77460025

Secondary line FX M77460021

Secondary line FX with Filter

M77460026

* K-Nect needle free access with Tru-Swab TM Technology, provides a fl at and smooth surface for optimal swabability, easy to clean to meet highest hygiene standards. It allows an easy and safe Luer-Lock connection of the secondary infusion to the primary infusion line.

Fresenius Kabi AGD-61346 Bad Homburg v.d.HGermanyPhone: +49 (0) 6172 686-0www.fresenius-kabi.com

5762

-0_b

ro_o

ncol

ogy_

volu

mat

_lin

es_e

ng

Intuitive and safe oncology infusion

Safe administration of IV Cytostatics and less risk of contamination with Oncology Volumat Lines

Excellent fl ow rate accuracyThe design of the silicone segment with a very precise diameter and high elasticity guarantees excellent fl ow-rate accuracy and infusion reliability of IV cytostatics.

Light protectionDrugs such as Irinotecan require light protection to guarantee the correct medication without any loss. The amber coloured Volumat Lines ensure a secure drug infusion by fi ltering all visible and uv light waves.

Free-fl ow protectionTo avoid any risk of free-fl ow, the patented 2 Safeclip on the Volumat Lines automatically clamps the line when the door is opened and when the set is removed. The risk of an unclosed roller clamp is eliminated. This protects the user from contamination with hazardous cytostatics.

Safe single drug therapyThe administration of a single drug therapy of IV cytostatics is intuitive and safe with the Oncology Volumat Lines in the Volumat Agilia Infusion pump range.

Proven cytostatic compatibility

All Fresenius Kabi Volumat Lines are certifi ed as compatible with cytostatic drugs by an external laboratory.1

Tested with oncology drugs, the materials used for all components of the Oncology Volumat Lines are proven to be free from side effects, such as contamination due to material cracking or toxic substances migration from the administration system.

Material compatibility guarantees a safe administration of hazardous IV cytostatics.

Perfect fl ow controlThe Volumat Lines have been especially designed for the Volumat Agilia pumps to provide a perfect fi t and control of the fl ow. Complete infusion reliability is achieved with the Occlusivity Check System – the only patented 3 autotest that checks the correct working order of the pump in association with its administration set.

Multi-drug therapy with secondary infusionThe Oncology Volumat Lines offer needle-free access ports for a safe and easy connection of secondary infusions according to the requirements of the oncology regimes. This “closed drug infusion system” avoids contamination and allows a complete drug delivery into the patient.

Volumat Agilia Infusion pumps are intuitive and easy-to-use ensuring maximum safety with a minimum workload.

Straightforward administration set installation: The set connectors have the same colour and shape as the dedicated slot in the pump.

Intuitive infusion set-up: Self-explanatory symbols on the keyboard. One key = one function. Set installation and infusion set-up in less than 25 seconds.

References

1 Supramol Parenteral Colloids GmbH, Germany: Compatibility of IV oncology drugs (e. g. Paclitaxel, Oxaliplatin, Irinotecan) with Fresenius Kabi cytostatic application sets; 2010

2 European Patent Application EP2089082

3 European Patent EP1031358